KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Non-Current Assets data on record, last reported at $273.4 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 847.0% year-over-year to $273.4 million; the TTM value through Dec 2025 reached $361.8 million, up 179.28%, while the annual FY2025 figure was $273.4 million, 847.0% up from the prior year.
  • Non-Current Assets reached $273.4 million in Q4 2025 per RIGL's latest filing, up from $27.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $273.4 million in Q4 2025 and bottomed at $5.2 million in Q3 2022.
  • Average Non-Current Assets over 5 years is $33.4 million, with a median of $18.8 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: crashed 66.47% in 2022, then surged 847.0% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $12.9 million in 2021, then surged by 42.88% to $18.4 million in 2022, then decreased by 2.27% to $18.0 million in 2023, then surged by 60.77% to $28.9 million in 2024, then soared by 847.0% to $273.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $273.4 million in Q4 2025, $27.6 million in Q3 2025, and $31.3 million in Q2 2025.